Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism

Erenus, Mithat; Yücelten, Deniz; Durmuşoğlu, Fatih; Gürbüz, Oya

doi:10.1016/s0015-0282(97)00371-3

Cited by 80 publications

(37 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the literature, the findings on finasteride and flutamide in hirsutism, nearly all calculated only on the Ferriman-Gallwey score, are controversial. Investigators who used both drugs with the same dosage as ourselves for 6-12 months report that finasteride decreases the Ferriman-Gallwey score from 11% (25) to 63.8% (26) in PCOS and from 10.6% (27) to 63% (28) in idiopathic hirsutism. Findings with flutamide range from 36.4% (29) to 53% (30) in PCOS and from 30.1% (31) to 70.9% (24) in idiopathic hirsutism.…”

Section: Discussionmentioning

confidence: 99%

RETRACTED: Comparison of finasteride versus flutamide in the treatment of hirsutism

Falsetti

Gambera

Legrenzi

et al. 1999

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: To compare the effectiveness of finasteride and flutamide in the treatment of hirsutism in patients with polycystic ovary syndrome (PCOS) and with idiopathic hirsutism. Design: Randomized study. Patients: One hundred and ten hirsute patients were selected: 64 women with PCOS and 46 with idiopathic hirsutism. Methods: Patients were assigned randomly to receive 5 mg finasteride once daily or 250 mg of flutamide twice daily, for 12 consecutive months. Hirsutism was evaluated at 12 months of therapy, with the Ferriman-Gallwey score and with measurement of the terminal hair diameters (mm) taken from four different body areas. Blood samples were taken for assessment of endocrine and hematochemical parameters. Side effects were monitored during the treatment. Results: Both finasteride and flutamide induced a significant decrease in the hirsutism scores and hair diameters at the end of 12 months. Finasteride reduced the Ferriman-Gallwey score by 31.4% in the PCOS cases and by 34.2% in the idiopathic hirsutism cases, and hair diameter by 27.0-34.1% in PCOS and by 29.6-37.9% in idiopathic hirsutism. Flutamide reduced the Ferriman-Gallwey score by 56.7% in PCOS and by 50.9% in idiopathic hirsutism, and hair diameter by 50.3-60.0% in PCOS and by 47.7-56.5% in idiopathic hirsutism. Flutamide did not induce hormone variations, while finasteride increased testosterone levels by 40% in PCOS and by 60% in idiopathic hirsutism and decreased 3a-androstanediol glucuronide (3a-diolG) by 66.7% in PCOS and by 69.5% in idiopathic hirsutism. No important side effects or changes in the hematochemical parameters were observed with finasteride, while two patients (3.6%) in the flutamide group expressed abnormal transaminase levels after 6 months of treatment. Dry skin also appeared significantly more with flutamide (67.3%) than with finasteride (23.6%). Conclusions: Both drugs are effective in the treatment of hirsutism but flutamide is more effective than finasteride.

show abstract

Section: Discussionmentioning

confidence: 99%

RETRACTED: Comparison of finasteride versus flutamide in the treatment of hirsutism

Falsetti

Gambera

Legrenzi

et al. 1999

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Couzinet et al [11] reported that it was possible to detect changes in the rate of hair growth after 6 months and a normalization of hirsutism scores at 12 months. Others also reported progressive results after 9 months or 1 year of treatment with similarly low doses of flutamide [5,10,16].…”

Section: Discussionmentioning

confidence: 94%

“…The decrease in serum DHEA-S concentration can be explained by additional effects of the OC components. In some studies, decreases in DHEA-S levels were reported in both flutamide and/or flutamide plus OC groups [10,19] but not in others [5,11].…”

Section: Discussionmentioning

confidence: 97%

“…It is thought that it forms inactive complexes with nuclear androgen receptors [3]. There are several reports that flutamide is effective in the treatment of hirsutism [4][5][6][7][8][9][10][11][12]. The aim of this study is to evaluate the clinical efficacy and safety of flutamide and to compare its use alone with using it in combination with an oral contraceptive (OC) including cyproterone acetate.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the Clinical Efficacy and Safety of Flutamide versus Flutamide plus an Oral Contraceptive in the Treatment of Hirsutism

Taner¹,

İnal²,

Başoğul³

et al. 2002

Gynecol Obstet Invest

View full text Add to dashboard Cite

Objective: To compare the clinical, hormonal, biochemical and hemotological effects of flutamide versus flutamide plus an oral contraceptive (OC) in the treatment of hirsutism. Patients: Eighty-four women with hirsutism were equally randomized to receive either flutamide or flutamide plus OC. Design: Eighty-four women with hirsutism were recruited from patients presenting to our hospital. Each patient underwent a complete medical and gynecological examination as well as blood cell counts, biochemical and endocrine profiles. Hirsutism scores and laboratory tests were done during the 1st, 3rd and 6th months of therapy. Thirty-seven women in the flutamide group (taking 250 mg flutamide per day) and 32 women in the flutamide plus OC group (taking 250 mg flutamide plus 35 µg ethinyl estradiol and 2 mg cyproterone acetate per day) regularly followed the therapy regimens. Results: There were no significant differences in Ferriman-Gallway scores at the beginning and at the end of the therapies between the two groups (p > 0.05). At the 6th month, the decreases in Ferriman-Gallway scores were significant in both flutamide (from 18.95 ± 4.44 to 14.46 ± 5.02; p < 0.05) and flutamide plus OC groups (from 19.94 ± 4.31 to 15.58 ± 4.28; p < 0.05). In the first group, 2 of 6 oligomenorrheic women had regular cycles at the end of the therapy. Oligomenorrhea in 8 women was all changed to regular cycles in the flutamide plus OC group. Regarding the hormonal profile, only in the second group were prolactin, free testosterone and dehydroepiandrosterone sulfate levels significantly decreased (p < 0.05). Hepatic function tests were significantly increased in both groups, but they were all within normal ranges. Conclusion: These data suggest that both therapies were similarly effective and safe in the treatment of hirsutism. In women with oligomenorrhea and/or needing contraception, adding an OC shows better results than flutamide treatment alone in providing regular cycles.

show abstract

“…Other trials suggested that spironolactone and flutamide were more effective than finasteride [27,28]. In women with hirsutism, finasteride is used in doses of 2.5-7.5 mg/d.…”

Section: Finasteridementioning

confidence: 99%

Hirsutism: Diagnosis and Treatment

Öner¹

2012

J Metabolic Synd

View full text Add to dashboard Cite

Hirsutism, which is a common clinical problem in women of reproductive age, is characterized by excessive growth of terminal hair in the androgen-sensitive skin regions. It is the result of either androgen excess or increased sensitivity of the hair follicles to normal levels of androgens. The therapeutic options of hirsutism can be divided into systemic, topical, and dermato-cosmetic therapies. Patients should be informed that the response to systemic agents is slow; occurring over 3-6 months after therapy has begun. In this review, the diagnosis and treatment of hirsutism were summarized with update literature.

show abstract

Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism

Cited by 80 publications

References 22 publications

RETRACTED: Comparison of finasteride versus flutamide in the treatment of hirsutism

RETRACTED: Comparison of finasteride versus flutamide in the treatment of hirsutism

Comparison of the Clinical Efficacy and Safety of Flutamide versus Flutamide plus an Oral Contraceptive in the Treatment of Hirsutism

Hirsutism: Diagnosis and Treatment

Contact Info

Product

Resources

About